Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
Saved in:
| Title: | Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children. |
|---|---|
| Authors: | Siemens A; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada., Brooks B; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada., Rassekh SR; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Oncology, Hematology and Bone Marrow Transplant, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada., Meijer AJM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands., Xu W; Department of Biostatistics, Dalla Lana School of Public Health, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Loucks CM; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada., Ross CJD; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada; and., Carleton BC; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.; BC Children's Hospital Research Institute, Vancouver, Canada.; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia.; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, Canada. |
| Corporate Authors: | Canadian Pharmacogenomics Network for Drug Safety Consortium |
| Source: | Therapeutic drug monitoring [Ther Drug Monit] 2023 Jun 01; Vol. 45 (3), pp. 345-353. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print Cited Medium: Internet ISSN: 1536-3694 (Electronic) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
